EV-302: Impact of Enfortumab Vedotin + Pembrolizumab in Metastatic Bladder Cancer

News
Video

Shifting their focus to metastatic bladder cancer, the Oncology Brothers and Rana McKay, MD, reflect on data from EV-302 and consider how enfortumab vedotin + pembrolizumab has shifted the treatment landscape.

Recent Videos
Toni K. Choueiri, MD, with the Oncology Brothers presenting slides
Related Content
Darolutamide Plus ADT Shows Efficacy and Safety Vs ADT Alone in mHSPC

Darolutamide Plus ADT Shows Efficacy and Safety Vs ADT Alone in mHSPC

Jonah Feldman
September 16th 2024
Article

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without docetaxel in the metastatic hormone-sensitive prostate cancer setting.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

Radium-223 Enhances Outcomes with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Radium-223 Enhances Outcomes with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Megan Hollasch
September 15th 2024
Article

Adding radium-223 to enzalutamide significantly improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases.

Read More

Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

Jordyn Sava;Nazli Dizman, MD
April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen

FDA Fast Tracks 64Cu-SAR-bisPSMA for Prostate Cancer Imaging

FDA Fast Tracks 64Cu-SAR-bisPSMA for Prostate Cancer Imaging

Jordyn Sava
August 22nd 2024
Article

64Cu-SAR-bisPSMA gained FDA fast track status for advanced prostate cancer imaging.

Read More

Lenvatinib Gets Updated Label to Include First-Line Efficacy in Advanced nccRCC

Lenvatinib Gets Updated Label to Include First-Line Efficacy in Advanced nccRCC

Jordyn Sava
August 20th 2024
Article

The US label for lenvatinib has been updated to include new clinical efficacy data for its use as a first-line treatment in advanced non-clear cell renal cell carcinoma, based on results from the KEYNOTE-B61 trial.

Read More